Citations

Clear

9383 citation(s) found for "Thomas, PS".

Can MRI Replace Nasopharyngoscopy in the Evaluation of Velopharyngeal Insufficiency?
Chee-Williams, Jessica L. , Perry, Jamie L. , Snodgrass, Taylor D. , Singh, Davinder , Temkit, M’hamed , Sitzman, Thomas J. , Sitzman, Thomas J , Singh, Davinder J , Chee-Williams, Jessica L , Snodgrass, Taylor , Perry, Jamie L

Mayo Clinic

The Cleft Palate Craniofacial Journal | March 15, 2024 | Volume: 62 | Issue: 7 | Pages: 1093-1102

10.1177/10556656241239459 | PMID 38490221 Get It

Objective To investigate whether flexible nasopharyngoscopy, when performed in addition to magnetic resonance imaging (MRI), influences the type of surgery selected or success of surgery in patients with velopharyngeal insufficiency (VPI). Design Cohort study. Setting A metropolitan children's hospital. Patients Patients with non-syndromic, repaired cleft palate presenting for management of VPI. Interventions MRI and nasopharyngoscopy or MRI alone for preoperative imaging of the velopharyngeal mechanism. Main Outcome Measures (1) Surgical selection and (2) resolution of hypernasality. All speech, MRI, and nasopharyngoscopy measurements were performed by raters blinded to patients’ medical and surgical history. Results Of the 25 patients referred for nasopharyngoscopy, 76% completed the exam. Of the 41 patients referred for MRI, the scan was successfully completed by 98% of patients. Completion of nasopharyngoscopy was significantly (p=0.01) lower than MRI. Surgical selection did not significantly differ (p=0.73) between the group receiving MRI and nasopharyngoscopy and the group receiving MRI alone, nor was there a significant difference between these groups in the proportion of patients achieving resolution of hypernasality postoperatively (p=0.63). Percent total velopharyngeal closure assessments on nasopharyngoscopy and MRI were strongly correlated (r=0.73). Conclusions In patients receiving MRI as part of their preoperative VPI evaluation, the addition of nasopharyngoscopy did not result in a difference in surgical selection or resolution of hypernasality. Routine inclusion of nasopharyngoscopy may not be necessary for the evaluation of velopharyngeal anatomy when MRI is available.
Impact of Procedure Time on First Pass Effect in Mechanical Thrombectomy for Anterior Circulation Acute Ischemic Stroke
Koo, Andrew B. , Renedo, Daniela , Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Levitt, Michael R. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Navía, Pedro , Kan, Peter , Spiotta, Alejandro M , Levitt, Michael R , Wolfe, Stacey Quintero , Navia, Pedro , Koo, Andrew B , Reeves, Benjamin C. , Jabbour, Pascal , Shaban, Amir , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Park, Min S. , Williamson, Richard, Sheth, Kevin N. , Havenon, Adam de , Matouk, Charles

Mayo Clinic

Neurosurgery | March 14, 2024 | Volume: 95 | Issue: 1 | Pages: 128-136

10.1227/neu.0000000000002900 | PMID 38483158 Get It

BACKGROUND AND OBJECTIVES: First pass effect (FPE) is a metric increasingly used to determine the success of mechanical thrombectomy (MT) procedures. However, few studies have investigated whether the duration of the procedure can modify the clinical benefit of FPE. We sought to determine whether FPE after MT for anterior circulation large vessel occlusion acute ischemic stroke is modified by procedural time (PT). METHODS: A multicenter, international data set was retrospectively analyzed for anterior circulation large vessel occlusion acute ischemic stroke treated by MT who achieved excellent reperfusion (thrombolysis in cerebral infarction 2c/3). The primary outcome was good functional outcome defined by 90-day modified Rankin scale scores of 0–2. The primary study exposure was first pass success (FPS, 1 pass vs ≥2 passes) and the secondary exposure was PT. We fit-adjusted logistic regression models and used marginal effects to assess the interaction between PT (≤30 vs >30 minutes) and FPS, adjusting for potential confounders including time from stroke presentation. RESULTS: A total of 1310 patients had excellent reperfusion. These patients were divided into 2 cohorts based on PT: ≤30 minutes (777 patients, 59.3%) and >30 minutes (533 patients, 40.7%). Good functional outcome was observed in 658 patients (50.2%). The interaction term between FPS and PT was significant ( P = .018). Individuals with FPS in ≤30 minutes had 11.5% higher adjusted predicted probability of good outcome compared with those who required ≥2 passes (58.2% vs 46.7%, P = .001). However, there was no significant difference in the adjusted predicted probability of good outcome in individuals with PT >30 minutes. This relationship appeared identical in models with PT treated as a continuous variable. CONCLUSION: FPE is modified by PT, with the added clinical benefit lost in longer procedures greater than 30 minutes. A comprehensive metric for MT procedures, namely, FPE 30 , may better represent the ideal of fast, complete reperfusion with a single pass of a thrombectomy device.
Medical Maintenance Therapy Following Laser Excision in Patients With Granulomatosis With Polyangiitis (GPA)‐Associated Subglottic Stenosis
Aden, Aisha A. , Awadallah, Andrew S. , Xie, Katherine , Wallerius, Katherine P. , O’Byrne, Thomas J., Bowen, Andrew J. , Edell, Eric S. , Bayan, Semirra L. , Ekbom, Dale C. , Xie, Katherine Z , Bowen, Andrew Jay , Awadallah, Andrew , Bayan, Semirra , Koster, Matthew J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 14, 2024 | Volume: 171 | Issue: 1 | Pages: 180-187

10.1002/ohn.694 | PMID 38482973 Get It

AbstractObjectiveTo report on a series of patients with cANCA/PR3‐positive, granulomatosis with polyangiitis (GPA)‐associated subglottic stenosis (SGS) and evaluate response to medical maintenance therapy with rituximab versus other immunosuppressants following initial endoscopic laser excision.Study DesignRetrospective chart review.SettingTertiary academic center.MethodsA retrospective chart review of patients with SGS and cANCA/PR3‐positive GPA who received immunosuppressive maintenance therapy following endoscopic laser excision at our institution from June 1989 to March 2020 was performed. Data pertaining to patient demographics, clinical features, medications, and endoscopic laser procedures were collected.ResultsA total of 27 patients (15 women) with mean age (range) of 40 (19‐59) years and mean (range) follow‐up of 12.6 years (1.5‐28.6) were identified. Sixteen patients (60%) had limited GPA. Six patients (24%) had previously received local intervention with open surgery (n = 1, 4%) or endoscopic techniques (n = 5, 20%). All patients experienced symptom improvement following initial CO2 laser excision at our institution without any procedural complications or adverse events. Following initial laser excision, 15 patients (60%) were treated with rituximab and 10 patients (40%) were treated with nonrituximab immunosuppressive agents. Patients treated with rituximab were less likely to recur (P = 0.040). Limited GPA was associated with an increased incidence of recurrence (P = 0.031). Median time (years) to recurrence (range) was 3.2 (0.3‐19.3) and was not significantly associated with treatment or GPA subtype.ConclusionEndoscopic CO2 laser excision is a safe and effective local intervention for GPA‐associated SGS. Medical maintenance therapy with rituximab reduces risk of recurrence following initial laser excision relative to treatment with non‐rituximab agents.
Palliative and End-of-Life Care in Hematologic Malignancies: Progress and Opportunities
Tsang, Mazie , LeBlanc, Thomas W. , Leblanc, Thomas , Tsang, Mazie

Mayo Clinic

JCO Oncology Practice | March 13, 2024 | Volume: 20 | Issue: 6 | Pages: 739-741

10.1200/op.24.00081 | PMID 38478797 Get It

@JCOOP_ASCO editorial on unique needs of end-of-life care for different blood cancers discusses: #pallheme improves QOL but less utilized in cancers. Contextualize Weisse et al study. More #pallheme research needed for lymphoma and myeloma in era of cell therapy
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
Imperiale, Thomas F. , Zella, Julia, Olson, Marilyn C. , Statz, Sandi, Garces, Jorge , Lavin, Philip T. , Aguilar, Humberto , Brinberg, Don, Berkelhammer, Charles , Porter, Kyle, Gagrat, Zubin D. , Porter, Kyle M. , Kisiel, John B. , Limburg, Paul J.

Mayo Clinic

New England Journal of Medicine | March 13, 2024 | Volume: 390 | Issue: 11 | Pages: 984-993

10.1056/nejmoa2310336 | PMID 38477986 Get It

Retrospective Review of Positive Newborn Screening Results for Isovaleric Acidemia and Development of a Strategy to Improve the Efficacy of Newborn Screening in the UK
Carling, Rachel S. , Hedgethorne, Katy, Chakrapani, Anupam , Flynn, Nick , Greenfield, Toby, Moat, Stuart J. , Ssali, Joshua, Shakespeare, Lynette , Taj, Nazia, Wu, Teresa Hoi-Yee , Ghosh, Arunabha , Lemonde, Hugh , Pierre, Germaine, Sharrard, Mark, Sreekantam, Sreevidya, Bonham, James R. , Flynn, Nick , Moat, Stuart J , Wu, Teresa H Y , Bonham, James R , Hall, Patricia , Anderson, Mark

Mayo Clinic

International Journal of Neonatal Screening | March 13, 2024 | Volume: 10 | Issue: 1 | Pages: 24

10.3390/ijns10010024 | PMID 38535128 Get It

Since the UK commenced newborn screening for isovaleric acidemia in 2015, changes in prescribing have increased the incidence of false positive (FP) results due to pivaloylcarnitine. A review of screening results between 2015 and 2022 identified 24 true positive (TP) and 84 FP cases, with pivalate interference confirmed in 76/84. Initial C5 carnitine (C5C) did not discriminate between FP and TP with median (range) C5C of 2.9 (2.0–9.6) and 4.0 (1.8–>70) µmol/L, respectively, and neither did Precision Newborn Screening via Collaborative Laboratory Integrated Reports (CLIR), which identified only 1/47 FP cases. However, among the TP cases, disease severity showed a correlation with initial C5C in ‘asymptomatic’ individuals (n = 17), demonstrating a median (range) C5C of 3.0 (1.8–7.1) whilst ‘clinically affected’ patients (n = 7), showed a median (range) C5C of 13.9 (7.7–70) µmol/L. These findings allowed the introduction of dual cut-off values into the screening algorithm to reduce the incidence of FPs, with initial C5C results ≥ 5 µmol/L triggering urgent referral, and those >2.0 and <5.0 µmol/L prompting second-tier C5-isobar testing. This will avoid delayed referral in babies at particular risk whilst reducing the FP rate for the remainder.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Wingard, John R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Uy, Geoffrey L. , Vasu, Sumithra, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Mikesch, Jan‐Henrik , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Marcucci, Guido , Geller, Nancy L. , Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason E. , Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Wittsack, Heather, Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Agura, Ed, Altman, Jessica K. , Anagnostopoulos, Achiles, Aulitzky, Walter E. , Balderman, Sophia , Ballen, Karen K. , Béguin, Yves , Berkahn, Leanne, Bilmon, Ian , Briggs, Adrienne, Brunstein, Claudio G. , Byrne, Michael , Carrum, George, Černý, Jan , Ciceri, Fabio , Colorado, Mercedes , Cook, Rachel J. , Couriel, Daniel R. , Damon, Lloyd E. , Deol, Abhinav , Desbrosses, Yohan, Devine, Steve, Grazia, Carmela Di, Stasi, Antonio Di , Dias, Ajoy , Dorritie, Kathy, Essell, James , Eto, Tetsuya , Forcade, Édouard , Frankfurt, Olga, Fukuda, Takahiro , Fürst, Sabine , Goto, Tatsunori , Hall, Aric C. , Hatta, Shunsuke , Hicheri, Yosr , Horwitz, Mitchell E. , How, Jonathan, Howard, Dianna S. , Hsu, Wei‐Hsun , Huynh, Anne , Irvine, David, Ishikawa, Takayuki , Jamieson, Katarzyna , Wiktor-Jędrzejczak, W , Karakasis, Dimitrios, Kato, Jun , Kekre, Natasha , Khera, Nandita , Klein, A. , Kobbe, Guido , Kornblit, Brian, Lachance, Silvy , Levis, Mark J., Lin, Tung‐Liang , Litzow, Mark, Liu, Ta‐Chih, Martelli, Maurizio , Matsuoka, Ken‐ichi , McCarty, John M. , Mendez, Lourdes , Michelis, Fotios V. , Mikesch, Jan-Henrik, Mineishi, Shin , Moors, Ine , Motyckova, Gabriela, Mueller, Lutz Peter , Muffly, Lori, Nakamae, Hirohisa , Nathan, Sunita , Norkin, Maxim , Ogawa, Yoshiaki, Olesen, G., Onozawa, Masahiro, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Perl, Alexander E., Piątkowska‐Jakubas, Beata, Protheroe, Rachel, Ross, Kelly , Santarone, Stella , Sawa, Masashi , Schaar, Dale , Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart , Shah, Nilay , Shah, Nirav N. , Gil, Jorge Sierra, Sobecks, Ronald , Sprague, Kellie , Spyridonidis, Alexandros , Stelljes, Matthias , Stiff, Patrick J. , Tandra, Anand, Tholouli, Eleni , Thomas, Xavier , Tomlinson, Benjamin , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Wagner, Eva , Watson, Anne-Marie, Wolschke, Christine, Yamauchi, Takuji , Yeh, Su‐Peng , Logan, Brent , Litzow, Mark R. , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Solh, Melham M , Mishra, Asmita , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Nagler, Arnon , Wei, Andrew H , Geller, Nancy , Hill, Jason , Gill, Stanley C , King, Denise , Devine, Steven , Horowitz, Mary , Chen, Yi-Bin , Hamadani, Mehdi , Ueda, Masumi , Waller, Edmund K. , Wei, Andrew H. , Devine, Steven M. , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Anagnostopoulos, Achiles, Anand, Sarah , Artz, Andrew , Becker, Michael W. , Berneman, Zwi Nisan , Bhatt, Vijaya Raj , Bonifazi, Francesca , Bruno, Benedetto , Byrne, Jenny , Cabrero, Mónica , Cairoli, Roberto , Cheong, June‐Won , Colorado, Mercedes , Craddock, Charles , Grazia, Carmela Di, Farag, Sherif Shafik , Fujiwara, Shin‐ichiro , Fukushima, Kentaro , Hou, Hsin‐An , Jethava, Yogesh S. , Jiménez, Antonio , Jung, Chul Won , Kanda, Junya , Klein, Andreas, Kota, Vamsi , Leber, Brian F. , Lee, Catherine J , Lee, Je‐Hwan , Levis, Mark J., Litzow, Mark, Martínez, Carmen , Mikesch, Jan-Henrik, Mohty, Mohamad , Mueller, Lutz, Muffly, Lori, Nakano, Nobuaki , Nicholson, Emma , Oluwole, Olalekan O. , Onozawa, Masahiro, Pantin, Jeremy , Perl, Alexander E., Poiré, Xavier , Rambaldi, Alessandro , Ritchie, David , Rubio, Marie‐Thérèse , Sanz, Jaime , Shore, Tsiporah B. , Socié, Gèrard , Stuart, Robert K. , Tanaka, Masatsugu , Tiribelli, Mario , Tsirigotis, Panagiotis D. , Tzachanis, Dimitrios , Uchida, Naoyuki , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Weisdorf, Daniel J. , Wróbel, Tomasz , Yakoub‐Agha, Ibrahim , Yared, Jean A. , Yoon, Sung‐Soo , Yoshihara, Satoshi

Mayo Clinic

Journal of Clinical Oncology | March 12, 2024 | Volume: 42 | Issue: 15 | Pages: 1766-1775

10.1200/jco.23.02474 | PMID 38471061 Get It

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202 ) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.
Negative Mood is Associated with Sociobehavioral Factors Contributing to Cardiovascular Risk in an Immigrant Population
Tranby, Brianna , Clark, Matthew M. , Novotny, Paul J. , Pardo, Laura Suarez, Iteghete, Sheila, Zeratsky, Katherine, Rieck, Thomas , Molina, Luz, Capetillo, Graciela Porraz, Ahmed, Yahye, Dirie, Hana, Tranby, Brianna N., Sia, Irene G. , Lohr, Abby M. , Patten, Christi A. , Iteghete, Sheila O, Zeratsky, Katherine A

Mayo Clinic

No container title available | March 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3934645/v1 | PMID 38559259 Get It

Abstract Background Immigrants to the United States, on average, accumulate cardiovascular risk after resettlement, including obesity. There is a need to co-create interventions to address these disparities, and mood may be an important mediating factor.Methods The Healthy Immigrant Community (HIC) study, set in southeast Minnesota, enrolled 475 adult participants in a weight loss intervention to reduce cardiovascular risk. Baseline questionnaires assessed mood, nutrition, physical activity, self-efficacy for healthy eating and physical activity, social support, and cohesion. A single-item mood rating of poor or fair was considered “negative”, while ratings of good, very good, or excellent were considered “positive”.Results A total of 449 HIC participants (268 Hispanic/Latino and 181 Somali) with complete baseline measures and were included in this analysis. Participants endorsing negative mood compared to those endorsing positive mood had lower scores for healthy eating (p = 0.02) and physical activity levels (p = 0.03), lower confidence in eating a healthy diet (p = 0.001), and felt less of a sense of belonging to their community (p = 0.01). Those endorsing negative mood also reported receiving less social support from their family and friends to eat healthy (p = < 0.001) and be physically active (p = 0.01), and less often accessed community resources for healthy eating (p = 0.001) and physical activity (p = < 0.01) compared to participants reporting positive mood.Conclusions Negative mood was associated with less healthy nutrition, lower confidence in eating healthy, sedentary lifestyle, and perceived lack of belonging to the community. Integrating mood management and self-efficacy strategies may enhance the effectiveness of lifestyle interventions among immigrants who report negative mood.ClinicalTrials.gov registration: NCT05136339; April 23, 2022
Understanding Team Dynamics and Culture of Safety Using Video Reflexive Ethnography During Real-Time Emergent Intubation
Garcia, Samuel I. , Finch, Alexander S. , Beckman, Thomas J. , Rivera, Mariela , Kennedy, Cassie C. , Kelm, Diana J. , Kennedy, Cassie C , Ridgeway, Jennifer L. , Montori, Víctor M. , Gajic, Ognjen

Mayo Clinic

Annals of the American Thoracic Society | March 12, 2024 | Volume: 21 | Issue: 7 | Pages: 1065-1073

10.1513/annalsats.202310-901oc | PMID 38470228 Get It

Abstract Rationale Endotracheal intubation is the third most common bedside procedure in U.S. hospitals. In over 40% of intubations, preventable complications attributable to human factors occur. A better understanding of team dynamics during intubation may improve patient safety. Objectives To explore team dynamics and safety-related actions during emergent endotracheal intubations in the emergency department and intensive care unit and to engage members of the care team in reflection for process improvement through a novel video-based team debriefing technique. Methods Video-reflexive ethnography involves in situ video recording and reflexive discussions with practitioners to scrutinize behaviors and to identify opportunities for improvement. In this study, real-time intubations were recorded in the emergency department and intensive care unit at Mayo Clinic Rochester, and facilitated video-reflexive sessions were conducted with the multidisciplinary procedural teams. Themes about team dynamics and safety-related action were identified inductively from transcriptions of recorded sessions. Results Between December 2022 and January 2023, eight video-reflexive sessions were conducted with a total of 78 participants. Multidisciplinary members included nurses (n = 23), respiratory therapists (n = 16), pharmacists (n = 7), advanced practitioners (n = 5), and physicians (n = 26). In video-reflexive discussions, major safety gaps were identified and several solutions were proposed related to the use of a multidisciplinary intubation checklist, standardized communication and team positioning, developing a culture of safety, and routinely debriefing after the procedure. Conclusions The findings of this study may inform the development of a team supervision model for emergent endotracheal intubations. This approach could integrate key components such as a multidisciplinary intubation checklist, standardized communication and team positioning, a culture of safety, and debriefing as part of the procedure itself.
Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care
Rowan, Courtney M. , Zambrano, Laura D. , Newhams, Margaret M. , Kücükak, Suden, McNamara, Elizabeth R, Mack, Elizabeth H. , Fitzgerald, Julie C. , Irby, Katherine , Schuster, Jennifer E. , Kong, Michele, Loftis, Laura L. , Kolmar, Amanda , Babbitt, Christopher , Nofziger, Ryan A. , Hall, Mark W. , Gertz, Shira J. , Zinter, Matt S. , Halasa, Natasha , Bradford, Tamara T. , McLaughlin, Gwenn E., Singh, Aalok R. , Staat, Mary Allen , Coates, Bria M. , Crandall, Hillary R, Maamari, Mia , Havlin, Kevin , Schwarz, Adam J. , Carroll, Christopher L. , Levy, Emily R. , Campbell, Angela P. , Randolph, Adrienne G. , Chou, Janet , Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Schwarz, Adam J, Harvey, Helen , Port, Emily, Shankman, Sara, Mansour, Rachel, Espinal, Paula S., Tarquinio, Keiko M. , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T, Newhams, Margaret M, Chen, Sabrina , Young, Cameron C, Carroll, Ryan W. , Yager, Phoebe H. , Flori, Heidi R. , Johnson, Brandi A., Drapeau, Noelle M., Malloch, Lacy , Martin, Lora, McGraw, Sarah , Schuster, Jennifer E, Cullimore, Melissa L. , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Kuebler, Joseph D. , Soma, Vijaya L, Doymaz, Sule , Schwartz, Stephanie P, Walker, Tracie C. , Lansell, Amanda , Hall, Mark W. , Burnett, Ryan H., Bush, Jenny L., Carcillo, Joseph A. , Butler, Andrew , Reed, Nelson, Stewart, Laura S , Golchha, Meena, Samperio, Marian, Qurashi, Jacob , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Martin, Lora , Randolph, Adrienne G , Levy, Emily R , Kong, Michele , Staat, Mary A , Gertz, Shira J , LaBere, Brenna , Young, Cameron C. , Maddux, Aline B. , Kong, Michele, Dapul, Heda , Schwartz, Stephanie P. , Bembea, Melania M. , Cvijanovich, Natalie Z , Hobbs, Charlotte V. , Wellnitz, Kari , Moffitt, Kristin , Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Schwarz, Adam J, Pannaraj, Pia S. , Giuliano, John S. , Michelson, Kelly Nicole , Sullivan, Janice E, Montgomery, Vicki , Bradford, Tamara T, Graciano, Ana Lía , Newhams, Margaret M, Young, Cameron C, Son, Mary Beth F. , Fernandes, Neil D. , Hume, Janet R. , Behl, Supriya , McGraw, Sarah, Schuster, Jennifer E, Spinella, Philip C. , McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , BIAGAS, KATHERINE V. , Schwartz, Stephanie P, Shein, Steven L. , Bush, Jenny, Thomas, Neal J. , Fink, Ericka L. , Reed, Nelson, Muñoz, Álvaro Coronado , McGuire, John K.

Mayo Clinic

Clinical Infectious Diseases | March 11, 2024 | Volume: 79 | Issue: 2 | Pages: 395-404

10.1093/cid/ciae133 | PMID 38465976 Get It

Abstract Background We aimed to determine if pre-existing immunocompromising conditions (ICCs) were associated with the presentation or outcome of patients with acute coronavirus disease 2019 (COVID-19) admitted for pediatric intensive care. Methods Fifty-five hospitals in 30 US states reported cases through the Overcoming COVID-19 public health surveillance registry. Patients &lt;21 years admitted 12 March 2020–30 December 2021 to the pediatric intensive care unit (PICU) or high-acuity unit for acute COVID-19 were included. Results Of 1274 patients, 105 (8.2%) had an ICC, including 33 (31.4%) hematologic malignancies, 24 (22.9%) primary immunodeficiencies and disorders of hematopoietic cells, 19 (18.1%) nonmalignant organ failure with solid-organ transplantation, 16 (15.2%) solid tumors, and 13 (12.4%) autoimmune disorders. Patients with ICCs were older, had more underlying renal conditions, and had lower white blood cell and platelet counts than those without ICCs, but had similar clinical disease severity upon admission. In-hospital mortality from COVID-19 was higher (11.4% vs 4.6%, P = .005) and hospitalization was longer (P = .01) in patients with ICCs. New major morbidities upon discharge were not different between those with and without ICC (10.5% vs 13.9%, P = .40). In patients with ICCs, bacterial coinfection was more common in those with life-threatening COVID-19. Conclusions In this national case series of patients &lt;21 years of age with acute COVID-19 admitted for intensive care, existence of a prior ICCs were associated with worse clinical outcomes. Reassuringly, most patients with ICCs hospitalized in the PICU for severe acute COVID-19 survived and were discharged home without new severe morbidities.